**2011 GROVER CONFERENCE ON RISK FACTORS IN PULMONARY HYPERTENSION: GENDER, SEX HORMONES, OBESITY, NOVEL GENETIC INFLUENCES AND RISK FACTORS**

**COURSE SCHEDULE**

### Wednesday, September 7, 2011

**12:00 pm - Arrivals**

**6.00 pm - Welcome Reception and Dinner**

### Thursday, September 8, 2011

**Session I (Part I): Genetic Risk Factors**  
**Chairs: Richard Trembath, Nicholas W. Morrell, Jim Loyd**

**6:55-7:55 am Breakfast**

**8:00 am**  
**Welcome and Introduction**  
E. Kenneth Weir, MD, Minneapolis, MN (University of Minnesota)

**8:10 am**  
**Update and Overview of Genetic Influences** (Including update on New Genetic Studies vs. Association Studies).  
James E. Loyd, MD, Nashville, TN (Vanderbilt University Center for Lung Research)

**8:45 am**  
**Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease.**  
K.E. Roberts, MD, Boston, MA (Tufts University Medical Center)

**9:20 am**  
**Novel Loci Interacting Epistatically With Bone Morphogenetic Protein Receptor 2 Cause Familial Pulmonary Arterial Hypertension.**  
David A. Greenberg, PhD, New York, NY (Columbia University)

**9:55 am**  
**Break (10 min)**

**10:05 am Estelle Grover Lecture**  
**A Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated with Idiopathic Pulmonary Arterial Hypertension.**  
Jason X-J Yuan, MD, PhD, San Diego, California (University of California San Diego)

**10:55 am microRNAs-control of Essential Genes: Recent Implications.**  
William T. Gerthoffer, PhD, Mobile, Alabama (University of South Alabama)

**11:30 am Risk Factors in PPHN**  
David N. Cornfield, MD, Palo Alto, CA (Stanford University)

**12:05 pm The Hypoxic Pulmonary Hypertensive Gene**  
John H. Newman, MD, Nashville, TN (Vanderbilt University School of Medicine)

**12:40 pm Lunch**

**Session I (Part II) Obesity as a Risk Factor**  
**Chairs: Norbert Voelkel, Matt Thomas, Novartis, Troy Stevens**

**3:00 pm Metabolic syndrome and PPARgamma**  
Antonio Vidal-Puig, MD, Cambridge, UK (University of Cambridge)

**3:45 pm Obesity and Thyroid Disease in Women with Severe Pulmonary Hypertension**  
Norbert Voelkel, MD, Richmond, VA (Virginia Commonwealth University Medical Center)
4:20 pm  Etiologies and Comorbidities in pulmonary hypertension: Insight from the REVEAL Registry  
David A. Badesch, MD, Aurora, CO (University of Colorado Denver)

4:55 pm  Exercise Capacity, COPD and Pulmonary Hypertension  
Matthew Thomas, PhD, UK (Novartis Institutes for BioMedical Research)

6:30 pm  Dinner

---

Friday, September 9, 2011

Session II (Part I). Endogenous factors and PAH  
Chairs: Sami Said, Ken Weir

6:55-7:55 am Breakfast

8:05 am  Terry Wagner Lecture  
Vasoactive Intestinal Peptide Gene is a Key Modulator of Pulmonary Vascular Remodeling and Inflammation  
Sami I. Said, MD, Stony Brook, NY (SUNY at Stony Brook)

8:55 am  C-type natriuretic peptides in the human circulation and relation to cardiac function  
A. Mark Richards, MD, PhD, Otago, New Zealand (University of Otago, New Zealand)

9:30 am  Adiponectin Deficiency: A Model of Pulmonary Hypertension Associated with Pulmonary Vascular Disease  
Kenneth Walsh, PhD, Boston, MA (Boston University School of Medicine)

10:05 am Break (10 min)

10:15 am  Apelin and Pulmonary Hypertension  
Charlotte Andersen, Copenhagen, Denmark (Pfizer Europe)

10:50 am  Adiponectin and Pulmonary Vascular Remodeling  
Benjamin D. Medoff, MD, Boston, MA (Massachusetts General Hospital)

12:00 pm Lunch

---

Session III (Part I). Estrogen metabolism and disease penetrance  
Chairs: John West, Karen Fagan, Mark Gillespie

4:00 pm  Alterations in estrogen metabolism: Implications for higher penetrance of FPAH in females  
Eric D. Austin, MD, Nashville, TN (Vanderbilt University)

4:35 pm  Young Investigator Award Talk chosen from submitted abstract  
TBD

5:00 pm  Gene Expression and CYP1B1 in BMPR2 Mutation Carriers with and without Evidence of Pulmonary Arterial Hypertension suggests Pathways Relevant to Disease Penetrance.  
James D. West, PhD, Nashville, TN (Vanderbilt University School of Medicine)

5:35 pm  Young Investigator Award. Talk chosen from submitted abstract

6:30 pm  Dinner
Saturday, September 10, 2011

Session III (Part II) Epigenetics
Chairs: Stephen Archer, Ivan McMurtry, Mandy MacLean

6:55-7:55 Breakfast

8:05 am Epigenetics and Cardiovascular Disease
Virginia H. Huxley, PhD, Columbia, MO (National Center for Gender Physiology, University of Missouri-Columbia)

8:50 am John Reeves Lecture
Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in PAH
Stephen L. Archer, MD, Chicago, IL (University of Chicago)

9:35 am Break (10 min)

Session III (Part III) Sex Hormones and PAH

9:45 AM Estradiol Metabolites and Progestins in Experimental PAH
Stevan P. Tofovic, DSc, MD, Pittsburgh, PA (University of Pittsburgh School of Medicine)

10:20 am Dehydroepiandrosterone and Experimental PAH
Masahiko Oka, MD, PhD, Mobile, AL (University of South Alabama)

10:55 am Serotonin, Estrogens and PAH
Mandy R. MacLean, PhD, Glasgow, UK (University of Glasgow)

11:30 am PPHN, serotonin as risk factor
Cassidy Delaney, MD, Aurora, Colorado (University of Colorado Hospital)

12:30 pm Lunch

Session IV
Risk Factors in Pulmonary Hypertension: Gender, Sex Hormones, Obesity, Novel Genetic Influences, and Novel Risk Factors
Facilitators/Chairs: Karen Fagan, Larissa Shimoda,

4:00 pm Abstract/Poster Review
7:00 pm Dinner

Sunday 11th September

Session V
2011 Risk Factors and Responsiveness to Current and Emerging Therapies
Chairs: John Westwick, Kurt Stenmark, Jason Yuan

7:00-8:00 am Breakfast

8:00 am Biomarkers in PAH – can we predict responsiveness to specific therapies?
Martin Wilkins, MD, London UK (Imperial College)

8:35 am Prostacyclin-Mediated Changes to Inflammation in PAH
Kurt R. Stenmark, MD, Denver, CO (University of Colorado Denver)
9:05 am  The effect of Sildenafil Treatment on TRPC Channels
         Jian Wang, PhD, Baltimore, MD (Johns Hopkins University)

9:40 am  Break (10 min)

9:50 am  Gender Differences in Vascular Reactivity to Endothelin-1
         Rita C. Tostes, PhD, Sao Paulo, Brazil (University of Sao Paulo)

10:25 am The Role of Medical Therapy in Non-PAH PH
         Marius M. Hoepner, MD, Hannover, Germany (Hannover Medical School)

11:00 am Vascular Progenitors in PAH – Biomarkers, Targets or Therapy?
         Nicholas W. Morrell, MD, Cambridge, UK (Cambridge University)

11:35 am Risk Factors and Responsiveness to Therapies in the Modern Era of PAH Treatment
         Oliver Sitbon, MD, Paris, France (Hopital Antoine Beclere)

12:10 pm Closing summary (10 min)
         Mandy MacLean and Karen Fagan

12:30 Lunch

Conference adjourns after lunch